Re-exploration of prognosis in type B thymomas: establishment of a predictive nomogram model

Author:

Zhao Ke1,Liu Lei1,Zhou Xiaoyun1,Wang Guige1,Zhang Jiaqi1,Gao Xuehan1,Yang Libing1,Rao Ke2,Guo Chao1,Zhang Ye1,Huang Cheng1,Liu Hongsheng1,Li Shanqing1,Chen Yeye1

Affiliation:

1. Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College

2. Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College

Abstract

Abstract Objective To explore the risk factors for disease progression after initial treatment of type B thymomas using a predictive nomogram model. Methods A single-center retrospective study of patients with type B thymoma was performed. The Cox proportional hazard model was used for univariate and multivariate analyses. Variables with statistical and clinical significance in the multivariate Cox regression were integrated into a nomogram to establish a predictive model for disease progression. Results A total of 353 cases with type B thymoma were retrieved between January 2012 and December 2021. The median follow-up was 58 months (range: 1-128 months). The 10-year progression-free survival (PFS) was 91.8%. The final nomogram model included R0 resection status and Masaoka stage, with a concordance index of 0.880. Non-R0 resection and advanced Masaoka stage were negative prognostic factors for disease progression (p < 0.001). No benefits of postoperative radiotherapy (PORT) were observed in patients with advanced stage and non-R0 resection (p = 0.114 and 0.284, respectively). Conclusion The best treatment strategy for type B thymoma is the detection and achievement of R0 resection as early as possible. Long-term follow-up is necessary, especially for patients with advanced Masaoka stage and who have not achieved R0 resection. No prognostic benefits were observed for PORT.

Publisher

Research Square Platform LLC

Reference27 articles.

1. Trends in Incidence and Survival of Patients With Thymic Epithelial Tumor in a High-Incidence Asian Country: Analysis of the Korean Central Cancer Registry 1999 to 2017;Shin DW;Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2022

2. The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?;Marx A;Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2022

3. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes;Marx A;Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2015

4. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting;Marx A;Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2014

5. Type B thymoma: is prognosis predicted only by World Health Organization classification?;Kim HK;The Journal of thoracic and cardiovascular surgery,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3